Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference [Seeking Alpha]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Seeking Alpha
TEM is guided to $1.59B revenue and $65M adjusted EBITDA in 2026, outpacing analyst expectations and de-risking the investment case. Diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200 and the xT CDx test priced at $4,500. TEM's AI-driven data moat, $1.1B backlog, and FDA-cleared ECG-AF algorithm position it as a leading healthcare AI platform with durable high-growth potential. BlackJack3D/E+ via Getty Images In December , I highlighted Tempus AI Inc. TEM ) as a Strong Buy , arguing that robust growth and a coming earnings inflection positioned the company for substantial gains. While only a month has This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TEM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business rel
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24Business Wire
- Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New GenesBusiness Wire
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and YieldBusiness Wire
TEM
Earnings
- 11/4/25 - Beat
TEM
Sec Filings
- 2/4/26 - Form 4
- 1/30/26 - Form 4
- 1/28/26 - Form 144
- TEM's page on the SEC website